NCT Number: NCT00159614
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
San Diego, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Stable congestive heart failure
- Impaired renal function
- Taking oral loop diuretic
Exclusion criteria
- Acutely decompensated (unstable) and end stage heart failure
- Diuretics other than loop diuretics
- Pregnant or nursing
- Inability to follow instructions
- Participation in another clinical trial within past 30 days
Treatment and study plan
Primary outcomes
-
Comparison of KW-3902IV alone or with loop diuretic on renal function.
Sponsors and collaborators
Lead sponsor
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Collaborators
- Merck Sharp & Dohme LLC
Registry information
Official study title
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment
Important dates
- Study start
- 2005
- First posted
- Sep 12, 2005
- Registry last updated
- Jan 29, 2008
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
NCT00270387
Cardiomyopathies, Cardiovascular Diseases
View Trial DetailsEfficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
NCT00520806
Cardiovascular Diseases, Female Urogenital Diseases
Chicago, Illinois, United States
View Trial DetailsFUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.
NCT00270361
Cardiomyopathies, Cardiovascular Diseases
View Trial DetailsA Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest
NCT00288730
Cardiomyopathies, Cardiovascular Diseases
View Trial Details